Foundation Medicine FoundationOne CDx
Foundation Medicine's FoundationOne CDx is now available in the US, following approval by the US Food and Drug Administration last year and finalization of a national coverage determination by the Centers for Medicare and Medicaid Services earlier this month. The test is available for patients with advanced solid tumor cancers. It assesses genomic alterations in 324 cancer genes and serves as a companion diagnostic for patients with certain types of non-small cell lung cancer, melanoma, colorectal cancer, ovarian cancer, and breast cancer to determine if they could benefit from one of 17 on-labeled therapies, of which 12 are approved as first-line therapy for their respective indication. In addition, the test reports genomic biomarkers, such as microsatellite instability and tumor mutational burden that can help inform the use of immunotherapies.
Human Longevity Health Nucleus X
Human Longevity this week launched Health Nucleus X and Health Nucleus X Platinum, direct-to-consumer membership-based health products that combine whole-genome sequencing with MRI and other modalities to reveal insights into four disease areas: cancer, cardiac, metabolic, and neurodegenerative/neurovascular. The Health Nucleus is a clinical research and discovery center that relies on the bioinformatics, machine learning, and other technical expertise of the HLI team. By integrating all the data generated through a Health Nucleus visit, clients are given actionable insight into their health, Human Longevity said. The HNX Membership product is $4,950 for the initial membership and $2,950 for subsequent years, and includes WGS, whole-body MRI, and eight other tests. The HNX Platinum Membership is $25,000 for the initial membership and includes two additional years of membership, with membership in subsequent years costing $6,000. In addition to WGS and MRI, the platinum product also includes 15 other tests.
Horizon Discovery Edit-R CRISPRa Arrayed CRISPR RNA Libraries
Horizon Discovery has released the Edit-R CRISPRa arrayed crRNA (CRISPR RNA) libraries, the newest addition to its CRISPR activation reagent platform from the recently acquired Dharmacon business. The new libraries can be used for drug discovery, pathway analysis, and disease progression studies, Horizon said. Edit-R synthetic crRNA arrayed libraries enable one-gene-per-well investigation. They also trigger the endogenous gene's expression, transcribing the gene in its native form. The Edit-R CRISPRa portfolio includes catalogue libraries for popular human and mouse gene families, such as ubiquitin enzymes, transcription factors, and kinases, in addition to druggable gene targets and the whole human genome. Bespoke collections are also available to support researchers working with a specialized gene target list.
For more new products and services, please visit the New Products page on our website.